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Malignant astrocytomas comprise anaplastic astrocytoma (AA; 
grade III) and Glioblastoma (GBM; grade IV). GBM is the most 
malignant with a median survival of 10–12 months in patients. 
Using cDNA microarray based expression profiling of different 
grades of astrocytomas, we identified several fold increased levels of 
PBEF1 transcripts in GBM samples. Pre-B-cell colony enhancing 
factor 1 gene (PBEF1) encodes Nicotinamide phosphoribosyl-
transferase (NAmPRTase), which catalyses the rate limiting step 
in the salvage pathway of NAD metabolism in mammalian cells. 
Further validation using real time RT-qPCR on an independent 
set of tumor samples (n = 91) and normal brain samples (n = 
9), GBM specific higher expression of PBEF1 was confirmed. 
Immunohistochemical staining for PBEF1 on a subset of the above 
samples largely reinforced our finding. We carried out ELISA 
analysis on serum samples of astrocytoma patients to determine 
whether this protein levels would correlate with the presence of 
tumor and tumor grade. PBEF1 serum levels were substantially 
elevated in many of the AA and GBM patients. Statistical analysis 
of these data indicates that in patients with astrocytoma, serum 
PBEF1 levels correlate with tumor grade and is highest in GBM. 
Immunohistochemical analysis of an independent set of 51 retro-
spective GBM cases with known survival data revealed that PBEF1 
expression in the tumor tissue along with its co-expression with 
p53 was associated with poor survival. Thus, we have identified 
PBEF1 as a potential malignant astrocytoma serum marker and 
prognostic indicator among GBMs.
Introduction
The most common of the brain cancers is astrocytomas, which 
occurs at a rate of almost 12 in 100,000 people.1 Astrocytomas may 
be either circumscribed (graded as Grade I/II) or diffuse. The diffuse 
type is being further divided into low-grade diffuse astrocytoma, 
(DA; Gr. II), anaplastic astrocytoma (AA; Gr. III) and glioblastoma 
multiforme (GBM; Gr. IV)2 with order of increasing malignancy. 
Patients with AA have an average survival of 3 years, whereas 
patients with grade DA have the best prognosis, with approximately 
5 years median survival. GBM patients have the worst prognosis 
with a median survival of approximately 12 months, even after 
surgical resection, radiation therapy and chemotherapy.3 GBMs are 
histologically characterized by nuclear atypia, high mitotic activity, 
microvascular proliferation and/or necrosis.
There is enough evidence in the literature about the presence of 
unrecognized clinically relevant subclasses of astrocytomas both with 
respect to their gene signature and their clinical response to therapy.4 
It has also been shown that histologically identical tumors behave 
differently for a given treatment protocol.4 While several genetic 
markers have been reported to be associated with different grades of 
astrocytoma, these markers do not allow identifying clinically rele-
vant factors predictive for outcome or response to therapy.5 Detailed 
investigation leading to complete understanding of mechanisms and 
their relevance in the cancer progression will allow us to develop 
cancer specific therapy by targeting deregulated pathways and design 
future treatment protocols tailored according to the biology of the 
individual tumors.6
Expression profiling using microarrays offers the option of unbiased, 
quantitative and reproducible tumor assessment by simultaneously 
evaluating thousands of individual gene expression measurements. To 
identify markers of prognostic and therapeutic utility in malignant 
astrocytomas, in particular GBM, we performed expression profiling 
of several samples of diffusely infiltrating astrocytomas comprising 
different grades and four normal brain tissue samples (pooled) as 
control using cDNA microarrays. Data analysis revealed PBEF1 to be 
a highly expressed gene among GBM samples. Initially PBEF1 was 
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identified as a cytokine namely pre-B-cell colony-enhancing factor 
1.7 Later, it was found that the protein encoded by PBEF1, namely 
Nicotinamide phosphoribosyltransferase (NAmPRTase) also func-
tions as an enzyme involved in the NAD biosynthesis. PBEF1 has 
also been recognized as a hormone named Visfatin as it was found 
in high levels in visceral fat.8 Although PBEF1 has been shown to be 
overexpressed in colon cancer, the role of PBEF1 in human cancers, 
in particular astrocytomas is largely not known.9 We have confirmed 
the GBM specific expression of PBEF1 by real time RT-PCR and 
immunohistochemical analysis on an independent set of tumor 
samples. We have shown that increased PBEF1 expression is indica-
tive of poor prognosis amongst GBM patients. More importantly, by 
estimation of serum PBEF1 levels in astrocytoma patients, we show 
that increase in serum PBEF1 levels correlate with tumor grade. 
These preliminary data suggest that PBEF1 levels may be an efficient 
and accurate indicator of tumor presence and grade and a potential 
prognostic marker in high grade neoplasms. To our knowledge, this is 
the first report, which clearly demonstrates the possible involvement 
of PBEF1 in cancer development, particularly astrocytoma.
Results
PBEF1/NAmPRTase/Visfatin is over expressed in malignant 
astrocytomas. cDNA microarray based expression profiling of mRNA 
derived from 25 diffusely infiltrating astrocytomas comprising 
different grades and four normal brain tissue was carried out. 
Analysis of microarray data identified several differentially regulated 
genes between normal brain tissue and different grades of astrocy-
toma (data not shown). Of the genes found to be expressed highly in 
GBMs, we found PBEF1 to be very interesting for variety of reasons. 
While PBEF1 was originally isolated as a presumptive cytokine 
named pre-B-cell colony-enhancing factor, it has been now shown 
to encode Nicotinamide phosphoribosyltransferase (NAmPRTase), 
which catalyses the rate limiting step in the salvage pathway of NAD 
metabolism in mammalian cells and regulates the function of the 
Sir2 ortholog, Sirt1, in mammalian cells.7,11 To further validate the 
grade specific expression of PBEF1, we measured the relative levels 
of PBEF1 transcripts by real-time RT-qPCR on an independent 
(different from those used for microarray analysis) set of tumor 
and normal samples (five DAs, thirty one AAs and fifty five GBMs 
and nine normal brain samples). We found that PBEF1 transcript 
levels were upregulated more than three fold (Log2 ratio = 1.585) 
in majority of GBMs (63.60%; 35/55 with a mean log2 ratio of 
2.48) in comparison to AAs (9.60%; 3/31 with a mean log2 ratio of 
0.44), DAs (0.00%; 0/5 with a mean log2 ratio of 0.50) and normal 
brain samples (0.00%; 0/9) with a p value <0.001 (Fig. 1). Further, 
to confirm the above results as well as correlate the RNA levels 
with protein levels in tumor samples, we analyzed tissue sections 
derived from a subset of above samples for which paraffin blocks 
were available. The staining pattern of PBEF1 was generally found 
to be granular and diffuse cytoplasmic. We found a vast majority of 
GBMs (72.22%; 26/36) found to be positive for PBEF1 staining 
(Fig. 2E and F). As expected, reduced percentage of samples among 
AAs (40.00%; 4/10) and DAs (20.00%; 2/10) showed PBEF1 posi-
tive staining (Fig. 2B and C). Further, the average percent positive 
tumor cells was found to be high among GBMs (37.50%) as against 
22.00% and 8.50% among AAs and DAs respectively suggesting the 
fact that PBEF1 is expressed in very high levels among GBMs. The 
staining of normal brain revealed that the glial cells are negative for 
PBEF1 staining (Fig. 2A).
Serum PBEF1 levels in astrocytoma patients correlate with 
grade. The concentration of Visfatin in plasma has been shown to 
increase during the development of obesity and in patients with type 
2 diabetes.12 On the basis of the above information and our results 
that PEBF1 is overexpressed in GBMs, PBEF1 appears to be a prom-
ising candidate serum marker for GBMs. To test whether PBEF1 
could be used as a clinical serum marker correlating with astrocytoma 
grade, we measured the levels of PBEF1 protein in available serum 
samples belonging to different grades and normal controls. Serum 
levels of PBEF1 were measured in 47 patients with GBM, 27 patients 
with AA, 6 patients with DA and 9 controls (Fig. 3). Comparisons of 
serum PBEF1 levels were made between different grades and normal 
as well as between different grades. The results of these comparisons 
are given in Table 1. Statistically significant differences were detected 
in PBEF1 serum levels in patients with different grades compared 
to controls: GBMs Vs controls (p < 0.001); AAs Vs controls (p = 
0.043) and DAs Vs controls (p = 0.018). Further, the serum PBEF1 
levels in patients with GBMs in comparison to that of AAs or DAs 
approached significance (AAs Vs GBMs, p = 0.066; DAs Vs GBMs, 
p = 0.066). No significant differences were detected between DAs 
and AAs.
Survival value of PBEF1. To analyze the survival value of PBEF1, 
we subjected a different set of 51 retrospective GBM cases where 
follow up was available, for expression of PBEF1. In GBM patients, 
while the prognostic significance of clinical variables in predicting 
survival have been clearly defined, altered protein expression of the 
well known genetic alteration found in these tumors, like overex-
pression of p53 and EGFR expression, have individually failed to 
give a clear cut prognostic significance, with confounding results 
in different studies.13-15 Therefore, for the purpose of multivariate 
analysis, we immunostained the sections to study the expression of 
p53 and EGFR in order to analyse the significance of their co-expres-
sion with PBEF1 with respect to patient survival.
Figure 1. Scatter plot of transcript levels of PBEF1 in different grades of astro-
cytoma. Log2-transformed gene expression ratios obtained from real-time 
quantitative PCR analysis are plotted for PBEF1. Each dot represents a data 
derived from one sample. In each sample, fold change in gene expression 
is calculated over its mean expression in normal brain samples. Three fold 
(Log2 ratio = 1.585) up regulation was considered significant.
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Figure 2. Immunohistochemical validation 
of PBEF1 overexpression in astrocytoma. 
Sections from normal brain—negative 
for staining (A), DA—negative for stain-
ing (B), AA—negative for staining (C), 
AA—positive for staining (D), GBMs—
positive for staining (E and F) were 
stained for PBEF1.
Correlating the expression of 
PBEF1 with survival among GBM 
patients, in univariate analysis, the 
median survival of the group which 
was positive for PBEF1 (black line) 
was lesser than that of the group 
negative for PBEF1 (grey dotted line), 
albeit with lack of  statistical signifi-
cance (12 months vs. 16 months 
respectively, p = 0.16; Fig. 4A). In 
multivariate analysis, while PBEF-1 
expression by itself did not corre-
late with survival, its co-expression 
with p53 showed a trend towards 
poorer survival. The median survival 
of the group positive for both the 
markers was 8 months (black line), as 
compared to 14 months (grey dotted 
line) of the group negative for both or 
either of them (p = 0.08; Fig. 4B). We 
also noted that radiotherapy, KPS at 
presentation and p53 expression were 
significant independent predictors of 
survival at all steps in the multivariate 
analysis (data not shown). The data 
put together suggest that PBEF1 is a 
potential prognostic marker amongst 
GBM patients particularly in combi-
nation with aberrant p53 expression.
Discussion
In this study, we found that both transcript and protein levels of 
PBEF1 are overexpressed in GBMs. Survival analysis indicated that 
GBM patients expressing higher level of PBEF1 in their tumors had 
a shorter survival. We show that the levels of PBEF1 protein can be 
reproducibly measured in serum of patients with malignant astro-
cytomas. Our data suggest that serum PBEF1 levels are very low in 
controls and that high levels are detected in astrocytoma patients. 
Furthermore, we demonstrate that increasing levels of serum PBEF1 
in patients corresponds to the grade of malignancy. The levels of 
serum PBEF1 in all the grades of astrocytoma was significantly 
different from that of normal controls. In addition, the patient serum 
belonging to malignant astrocytoma (AAs and GBMs) had substan-
tially higher levels of PBEF1 than the lower grade patients (DAs) 
with difference approaching statistical significance.
Pre-B cell colony-enhancing factor 1 (PBEF)/Visfatin/
Nicotinamide phosphoribosyl transferase (NAmPRTase) is a multi-
functional protein having phosphoribosyl transferase, cytokine and 
adipokine activities.7,11 PBEF1 has been shown to inhibit apoptosis 
Figure 3. Scatter plot of serum PBEF1 levels. Serum levels of PBEF1/Visfatin 
(ng/mL) in normal controls (n = 9), DAs (n = 6), AAs (n = 27) and GBMs (n 
= 45) are plotted. Horizontal line—designates the mean value.8
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in neutrophils.16 Visfatin has been found to be elevated in serum of 
patients with type 2 diabetes mellitus in human and animal models.12 
An increase in Visfatin plasma concentration has been demonstrated 
in during obesity development and in patients with type 2 diabetes.12 
The role of PBEF1 in the biology of human solid tumors is unclear. 
Given the relative specificity of increased expression in GBMs rela-
tive to anaplastic astrocytomas, it is possible that PBEF1 protein is 
an integral component of GBM development and/or may contribute 
to GBM-specific histological characteristics, which distinguish them 
from lower grades of astrocytoma. It is also possible that elevated levels 
of PBEF1 in GBMs may deregulate signaling pathways resulting in 
activation of pro-survival pathways and chemoresistance. Indeed, 
it has been shown that NAmPRTase can inhibit apoptosis under 
experimental conditions in neutrophils and impart chemoresistance 
in cancer cells.16,17 PBEF1 overexpression has also been shown to 
predict poor response to doxorubicin-based primary chemotherapy 
in breast cancer patients.18 Further, NAD+, the final product of 
salvage pathway catalyzed by NAmPRTase, is an essential coenzyme 
that is also used as a substrate in several biochemical reactions, 
such as those catalyzed by poly (ADP-ribose) polymerase (PARP1), 
sirtuins and ADP-ribosyl cyclase.19 In particular, NAmPRTase, the 
rate-limiting component in the NAD+ biosynthesis pathway, regu-
lates the function of the Sir2 ortholog, Sirt1, in mammalian cells.11 
A potent inhibitor of NAmPRTase, FK866, can reduce cellular NAD 
+ levels and induce apoptosis in tumors.20
Thus the overexpression of PBEF1/NAmPRTase in GBM patients 
may result in poor survival and open room for developing thera-
peutic small molecules targeting this enzyme. Indeed the survival 
analysis in our study suggests a prognostic value for PBEF1 expres-
sion. Taken together, we have identified PBEF1 as a potential grade 
specific astrocytoma serum marker of prognostic importance. More 
importantly, this marker could serve as a potential therapeutic target 
for malignant astrocytoma.
Materials and Methods
Tumor samples. Tumor samples were collected from patients, 
who were operated at Manipal Hospital, Sri Satya Sai Institute of 
Higher Medical Sciences and National Institute of Mental Health 
and Neurosciences, Bangalore, India. Normal brain tissue samples 
(anterior temporal lobe) obtained during surgery for intractable 
epilepsy were used as control samples. A total of 100 samples which 
Table 1 Statistical analysis of serum PBEF1 levels
Comparison categories  Group I  Group II  p value Significancec 
(Group I vs Group II)
 Mean SEMa SDb Median Mean SEM SD Median
Normals Vs GBMs 3.49 0.68 2.06 2.70 27.54 4.68 31.43 14.50 <0.001 Significant
Normals Vs AAs 3.49 0.68 2.06 2.70 14.28 3.01 15.64 8.40 0.043 Significant
Normals Vs DAs 3.49 0.68 2.06 2.70 7.63 1.21 2.98 6.75 0.018 Significant
AAs Vs GBMs 14.28 3.01 15.64 8.40 27.54 4.68 31.43 14.50 0.066 Approaching significance
DAs Vs GBMs 7.63 1.21 2.981 6.75 27.54 4.68 31.43 14.50 0.066 Approaching significance
DAs Vs AAs 7.63 1.21 2.981 6.75 14.28 3.01 15.64 8.40 0.692 Not significant
aStandard error of mean; bStandard deviation; cp < 0.05 is considered significant.
Figure 4. PBEF1 expression and survival of patients with GBM. Kaplan-Meier 
survival estimates for 51 GBM patients are calculated for p53, EGFR1 and 
PBEF1 staining. (A) Survival curves for the groups positive and negative for 
PBEF1 in univariate analysis. The cases which were positive for PBEF1 (black 
line) had a poorer survival than the cases which were negative (grey line) 
(p = 0.16), (B) Survival curves for the groups positive and negative for co-
expression of p53 and PBEF1, in multivariate analysis. The group positive for 
both the markers (black line) had a poor survival as compared to the group 
negative for both or either of them (grey dotted line).
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included different grades of astrocytomas [(five DAs (Gr. II), thirty 
one AAs (Gr. III) and fifty five GBMs (Gr IV)] and nine normal 
brain samples were used in this study. Tissues were bisected and one 
half was snap-frozen in liquid nitrogen and stored at -80°C until 
RNA isolation. The other half was fixed in formalin and processed 
for paraffin sections and these were used to identify the histopatho-
logical analysis and immunohistochemistry.
Serum collection. Blood samples were collected from patients 
diagnosed to have diffuse astrocytoma of varying grades prior to 
surgery. Control blood samples were collected from patients who 
were operated for intractable epilepsy (where normal brain tissue 
served as control for RT-qPCR and immunohistochemistry). The 
blood samples were allowed to clot at room temperature for no more 
than 72 hrs, and were then centrifuged at 4°C for 5 min at 1000 
rpm. The serum (upper phase) was separated and stored at -20°C 
until use.
RNA isolation and RT-qPCR. Total RNA was extracted from 
the frozen tissue by TRI® Reagent (Sigma, USA). The RNA samples 
were quantified by measuring the absorbance using a spectropho-
tometer and visualized on a MOPS-Formaldehyde gel for quality 
assurance. The relative quantitation of expression levels of selected 
genes was carried out using two step strategy: in the first step, cDNA 
was generated from RNA derived from different tissue samples using 
cDNA Archive kit (ABI PRISM); subsequently real-time quantita-
tive PCR was carried out in ABI PRISM 7900 (Applied Biosystems) 
sequence detection system with the cDNA as template using gene 
specific primer sets and Dynamo kit containing SYBR green dye 
(Finnzyme, Finland). All measurements were made in triplicate. The 
genes RPL35A (ribosomal protein L35a), AGPAT1 (1-acylglycerol-
3-phosphate O-acyltransferase 1), ATP5G1 (ATP synthase, H+ 
transporting, mitochondrial F0 complex, subunit C1 (subunit 9)) 
and GARS (glycyl-tRNA synthetase) were used as internal controls as 
their expression levels were found to be unaltered in the array experi-
ments. Normal brain tissue samples from nine different epilepsy 
patients were used as reference. Delta delta CT method was used 
for the calculation of expression ratios. An increase or decrease in 
gene expression by 3 fold (log2 ratio = 1.585) or more over its mean 
expression in reference samples was considered significant. Statistical 
significance was tested by Mann-Whitney test using GraphPad 
PRISM® software. Sequences of RT-PCR primers and conditions 
used will be provided on request.
ELISA assay. PBEF1 levels were determined for all of the serum 
samples, using the Visfatin EIA kit from ALPCO Diagnostics 
according to the manufacturer’s protocol. Absorbance was read using 
Molecular Devices SPECTRAMax® 340PC Microplate Reader. 
Protein concentrations were estimated by interpolation of the non-
linear regression curve plotted using four parameter logistic equation. 
To compare the differences between the data obtained from different 
groups, Mann-Whitney test was performed. A P value of less than 
0.05 was considered as statistically significant difference between the 
compared data sets. GraphPad PRISM® Version 4.0 was used for 
these purposes.
Histopathology and immunohistochemistry (IHC). Histological 
sections of normal brain and tumor tissues were examined by light 
microscopy using hematoxylin and eosin (H&E) preparation. Tumor 
sections of diffusely infiltrating astrocytomas were graded using the 
WHO grading scheme.10 Paraffin sections (4 μm) from the tumor 
tissue and control samples were collected on silane coated slides and 
IHC for PBEF1 was carried out as follows: rabbit polyclonal anti-
body against purified GST-PBEF1 protein was made using standard 
immunization protocol. Microwave antigen retrieval was done at 400 
watt for 18 mins in 10 mM citrate buffer, pH 6.0. The sections were 
further treated with methanol and 5% hydrogen peroxide to block 
endogenous peroxidase followed by washes with PBS buffer (pH 7.6). 
Skimmed milk powder (5%) was used to block background staining 
for 45 mins. The sections were incubated with the primary antibody 
(diluted to 1:1000) at room temperature for 2 hours. This was 
followed by incubation with supersensitive non-biotin HRP detec-
tion system (QD440-XAK, Biogenex). “3,3'-Diaminobenzidine” 
(Sigma) was used as the chromogenic substrate.
The staining pattern of PBEF1 was found to be granular and 
diffuse cytoplasmic. A staining intensity of 3+ in the tumor cell cyto-
plasm with more than 30% cells showing positive staining was taken 
to consider the tumor to be positive. GBM tumor samples showing 
significantly high expression of mRNA levels by RT PCR was taken 
as positive control. A negative control slide in which the primary 
antibody was excluded was incorporated with each batch of slides.
Immunohistochemistry for PBEF1 expression in archival 
samples of GBM to assess the survival value of PBEF1. To analyze 
the survival value of PBEF1, we subjected a different set of 51 retro-
spective GBM cases where follow up was available, for expression 
of PBEF1 along with p53 and EGFR by immunohistochemical 
analysis. Case records of GBM patients operated in the year 2002 
were retrospectively analyzed and follow up data collected. Postal 
questionnaires were sent to all these patients, requesting their present 
functional status and date of expiry, when appropriate. Of these, 51 
cases of adult, supratentorial, lobar GBM patients who underwent 
an open surgery, and had at least one post-operative follow-up, were 
selected and were shown to be representative of the total 96 cases of 
GBM operated in that year, by independent samples T-test.
The mean age of the patients in the retrospective group analyzed 
was 45.3 years (Range: 18–80 yrs) and their mean Karnofsky 
Performance Status (KPS) at presentation was 60.9 (Range: 30–90). 
35 of these 51 patients (68.6%) underwent near-total/gross-total 
resection, and a sub-total resection was achieved in the rest. All the 
patients were referred for adjuvant therapy. The median duration of 
follow-up was 8 months (Range: 1–53 months).
The formalin fixed, paraffin embedded blocks of the 51 cases were 
retrieved. Fresh sections (4 μm) were collected on silane coated slides 
and immunostained for PBEFI, p53 (monoclonal: DO-7, Biogenix, 
USA, diluted to 1:200) and EGFR (monoclonal: E-30, Biogenix, 
USA, diluted to 1:50). For p53 staining, antigen retrieval was 
performed similar to that for PBEF1, but for 25–35 mins at 700 W. 
For EGFR staining, the sections were pretreated with Tris-EDTA pH 
9.0 at 600 W for 30 mins. For p53 and EGFR, brain tumor samples 
previously characterized for their overexpression were used as positive 
controls. p53 and EGFR immunoreactivity was considered positive 
when more than 20% of tumor cells stained positively (nuclear and 
membrane cytoplasmic labeling respectively). A cut off of 50% cell 
positivity for PBEF1 was considered for statistical analysis
Statistical analysis was done using SPSS 10.0 software. For univar-
iate analysis, Kaplan-Meier survival curves with Log-Rank statistical 
correlations were employed. Multivariate analysis was done using 
Cox proportional hazard model (Enter method) using age, operative 
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extent of resection, KPS at presentation, radiotherapy, p53 expres-
sion and EGFR overexpression as the constant clinical co-variants 
and adding PBEF1 expression to these.
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